Overview

MPDL3280A-treatment-IST-UMCG

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

To be able to evaluate the investigational imaging - 89Zr-MPDL3280A-PET, 89Zr-CD8 imaging and 18F-FB-IL2-PET - as complementary tools for selection of patients to be treated with MPDL3280A, within this treatment trial the investigators will assess safety, tolerability and anti-tumor activity of MPDL3280A in cancer patients, who have undergone investigational imaging.

Phase:

Phase 2

Details

Lead Sponsor:

University Medical Center Groningen

Treatments:

Antibodies, Monoclonal
Atezolizumab